What question did this study set out to answer?

To document and assess reports of secondary T-cell malignancies occurring after chimeric antigen receptor T-cell administration.

January 24, 2024New England Journal of Medicine

Secondary Cancers after Chimeric Antigen Receptor T-Cell Therapy

View Full Paper

Ask AI

Bookmark

Authors

NVNicole VerdunCenter for Biologics Evaluation and Research PMPeter MarksBoston University

Discussion

Member takes

Implication

Regulatory safety surveillance reports rare secondary T-cell cancers in patients receiving CAR-T therapy, highlighting the need for ongoing adverse event monitoring.

Key Points

To document and assess reports of secondary T-cell malignancies occurring after chimeric antigen receptor T-cell administration.
FDA safety surveillance and adverse event monitoring of patients treated with approved CAR-T products through December 31, 2023.
Identified 22 cases of secondary T-cell cancers occurring after treatment with CAR-T cell products.
Secondary T-cell malignancies currently represent relatively rare adverse events following CAR-T therapy.

Cite This Study

Verdun et al. (2024) studied this question.

synapsesocial.com/papers/6a0f9bc2d8c5cf602efcee54 https://doi.org/10.1056/nejmp2400209

View Full Paper

Ask AI

Bookmark

Implication

Regulatory safety surveillance reports rare secondary T-cell cancers in patients receiving CAR-T therapy, highlighting the need for ongoing adverse event monitoring.

Secondary Cancers after Chimeric Antigen Receptor T-Cell Therapy

Discussion

Member takes

Implication

Key Points

Cite This Study

Secondary Cancers after Chimeric Antigen Receptor T-Cell Therapy

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider